Stories from MedEsthetics
Friday, January 6, 2017 - 11:00
Revance Therapeutics commenced a pair of double-blind, placebo-controlled, North American Phase 3 trials to evaluate single injections of drug candidate DaxibotulinumtoxinA (RT002) for the treatment of glabellar lines in about 600 total patients. The trials follow the successful BELMONT study that showed RT002 delivered six-month duration of effect, with no ptosis at the 40-unit level, in treating frown lines.
Friday, January 6, 2017 - 10:56
Allergan has received approval from the U.S. Food and Drug Administration (FDA) to market Natrelle Inspira SoftTouch breast implants, a new medium firmness, cohesive gel option for women undergoing breast reconstruction, augmentation or revision surgery.
Wednesday, January 4, 2017 - 09:19
FEATURES PDT for skin rejuvenation »A Light Boost
Thursday, December 29, 2016 - 12:08
In an article published in Plastic and Reconstructive Surgery (January 2017), Jack F. Scheuer III, MD, et al, outline general principles and safe practices for ensuring increased safety and better outcomes when administering facial filler injections. They posit that practitioners can tailor injection techniques to prevent vessel injury and avoid cannulation by considering the depth and the location of the vasculature within six “facial danger zones,” i.e., brows/glabella, temporal region, infraorbital area, lips/commissure, nasolabial folds and nose.
Thursday, December 29, 2016 - 12:03
AirXpanders has received U.S. Food and Drug Administration (FDA) de novo clearance for the AeroForm Tissue Expander System, a Class II medical device used for breast reconstruction following mastectomy. The needle-free device is activated by a handheld wireless controller that administers programmed amounts of CO2 (up to three times a day) to gradually stretch the tissue. Clinical data demonstrated that patients who used the device safely achieved full expansion in weeks (rather than months) and completed their reconstruction faster than with traditional, saline-based expanders.
Thursday, December 29, 2016 - 12:01
The U.S. Food and Drug Administration (FDA) has released a new draft guidance on the post-market management of medical device cyber security, a response to ever-evolving technology, and hence, increased risk of cyber breaches that could affect devices’ functionality throughout their life cycles. It complements an earlier final guidance issued in October 2014. This new guidance outlines steps the FDA recommends manufacturers take to continually manage cyber security risks, including:
Thursday, December 29, 2016 - 11:57
Allergan and Acelity announced that they have entered into a definitive agreement under which Allergan has agreed to acquire the regenerative medicine company LifeCell for $2.9 billion in cash, subject to customary adjustments.
Friday, December 16, 2016 - 09:38
Galderma has received U.S. Food and Drug Administration (FDA) approval of two new Restylane products for the treatment of nasolabial folds (NLF) in patients over the age of 21. Restylane Refyne is approved for the treatment of moderate to severe facial wrinkles and folds, and Restylane Defyne for the treatment of moderate to severe, deep facial wrinkles and folds.
Friday, December 16, 2016 - 09:33
A recent study, published in the Journal of Drugs in Dermatology (December 2016), evaluated the efficacy, tolerability and safety of a novel topical formulation containing high levels of physiological barrier lipids in a cholesterol-dominant ratio to address the epidermal lipid imbalances of aging skin.
Friday, December 16, 2016 - 09:15
Valeant Pharmaceuticals International announced that William D. Humphries has been appointed executive vice president, dermatology, effective January 2, 2017. He will join Valeant’s Executive Committee, reporting directly to the company’s chairman and CEO, Joseph C. Papa.
Wednesday, December 7, 2016 - 12:23
A study published online December 2, 2016, in the Aesthetic Surgery Journal sought to evaluate the impact of a plastic surgeon’s gender on patient choice.
Wednesday, December 7, 2016 - 12:06
A study published in the Journal of Drugs in Dermatology (December 2016) found that the BTL Vanquish ME (Maximum Energy) from BTL Aesthetics was effectively redesigned for more efficient and homogenous energy delivery to targeted tissue, reducing 53% more fat versus the BTL Vanquish. The BTL Vanquish ME, which debuted in 2015, is FDA-cleared for the circumferential reduction of the abdomen and thighs.
Wednesday, December 7, 2016 - 11:42
Cutera has introduced the PICO Genesis, a new nonthermal approach for the treatment of pigmentary skin concerns using the Enlighten picosecond laser system. The procedure uses ultra-short laser pulses that deliver a shockwave effect to selectively shatter pigment, and disrupt and remodel the upper dermis for a brighter, more uniform complexion. It takes about 20 minutes from start to finish, is pain-free and requires very little downtime.
Friday, December 2, 2016 - 14:51
Who is MedEsthetics for?MedEsthetics is a business resource for physicians and other professionals in the medical aesthetics industry that provides information on the latest treatments, anti-aging and medical breakthroughs, product and equipment reviews, legal issues, profiles of successful practitioners, effective marketing and management strategies, and industry news.
Friday, December 2, 2016 - 13:00
Contact: Lisa Fisco, Associate Publisher 800.442.5667 ext email@example.com Click here to download the 2017 media kit »
Thursday, December 1, 2016 - 15:32
The American Society for Dermatologic Surgery (ASDS) announced the 2016 recipients of the Fredric S. Brandt, MD, Innovations in Aesthetics Fellowship Fund at the recent 2016 ASDS Annual Meeting in New Orleans. Yakir Levin, MD, PhD, and Omer Ibrahim, MD, will each receive a $25,000 clinical research grant through the program, established in 2015 to continue the legacy of Dr. Brandt. The grants are funded by The Allergan Foundation and support the career development of junior cosmetic dermatologic surgeons focused on cosmetic treatments and patient care.
Thursday, December 1, 2016 - 15:29
Today’s aesthetic consumers want procedures that offer visible results with minimal downtime performed in a nurturing, relaxing environment. In response, many medical and spa professionals have turned their attention to medical spas. Medical spas have experienced dramatic growth in recent years, bringing in an estimated $1.8 billion in sales in 2013, along with a highly significant 18 percent year-over-year growth, according to Marketdata Enterprises.
Thursday, December 1, 2016 - 15:25
Foamix Pharmaceuticals has completed patient enrollment in two Phase 3 clinical trials to evaluate the efficacy and safety of FMX101, a topical 4% minocycline foam, in the treatment of moderate to severe acne. The pivotal trials will be conducted simultaneously, and Foamix expects to report topline results in the first half of 2017.